{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Berois N"],"funding":["Programa Grupos de Investigación, CSIC, Universidad de la República, Uruguay"],"pagination":["645"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8833780"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(3)"],"pubmed_abstract":["Aberrant glycosylation is a hallmark of cancer and can lead to changes that influence tumor behavior. Glycans can serve as a source of novel clinical biomarker developments, providing a set of specific targets for therapeutic intervention. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs) suitable for selective cancer-targeting therapy. The best characterized TACAs are truncated O-glycans (Tn, TF, and sialyl-Tn antigens), gangliosides (GD2, GD3, GM2, GM3, fucosyl-GM1), globo-serie glycans (Globo-H, SSEA-3, SSEA-4), Lewis antigens, and polysialic acid. In this review, we analyze strategies for cancer immunotherapy targeting TACAs, including different antibody developments, the production of vaccines, and the generation of "],"journal":["Cancers"],"pubmed_title":["Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives."],"pmcid":["PMC8833780"],"funding_grant_id":["COF 03/11","number 908"],"pubmed_authors":["Berois N","Pittini A","Osinaga E"],"additional_accession":[]},"is_claimable":false,"name":"Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.","description":"Aberrant glycosylation is a hallmark of cancer and can lead to changes that influence tumor behavior. Glycans can serve as a source of novel clinical biomarker developments, providing a set of specific targets for therapeutic intervention. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs) suitable for selective cancer-targeting therapy. The best characterized TACAs are truncated O-glycans (Tn, TF, and sialyl-Tn antigens), gangliosides (GD2, GD3, GM2, GM3, fucosyl-GM1), globo-serie glycans (Globo-H, SSEA-3, SSEA-4), Lewis antigens, and polysialic acid. In this review, we analyze strategies for cancer immunotherapy targeting TACAs, including different antibody developments, the production of vaccines, and the generation of ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T08:01:35.873Z","creation":"2025-04-04T08:01:35.873Z"},"accession":"S-EPMC8833780","cross_references":{"pubmed":["35158915"],"doi":["10.3390/cancers14030645"]}}